Combination of lapatinib and trastuzumab shrinks HER2 positive breast cancer
Approximately a quarter of women with HER2 positive breast cancer, who were treated with a combination of the targeted drugs lapatinib and trastuzumab before surgery and chemotherapy, saw their tumours shrink significantly or even disappear, according to results from a clinical trial. The University of Manchester
